N = 92 respondents 4 Discussion In this patient survey, responden

N = 92 respondents 4 Discussion In this patient survey, respondents with chronic angina who did not have a history of revascularization reported substantial improvement in QoL, angina frequency, and angina severity after initiating therapy with ranolazine. These improvements represent key treatment goals established by ACC/AHA guidelines for patients with chronic stable angina. Chronic stable angina can have a significant negative impact on daily activities and QoL of patients with CHD [13]. Invasive procedures such as PCI, coronary artery bypass grafting, and stenting

have been shown to improve QoL in patients with severe angina [14, 15]. However, many patients with stable ischemic heart disease may benefit from medical therapy [16]. Interestingly, among patients with BVD-523 supplier stable angina in the RITA-2 (Second Randomized Intervention Treatment of Angina) and COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluations) trials, early superiority of PCI over medical therapy in improving QoL had attenuated

by 3 years, although this observation may RXDX-106 cell line be attributable in part to patients assigned to medical therapy subsequently undergoing invasive treatment [15, 17]. In COURAGE, patients with more severe and more frequent angina were found to gain the greatest benefit from PCI [15]. Ranolazine can be used as initial anti-anginal therapy (particularly in situations where there is a contraindication to traditional anti-angina medications, or a concern about decreases in blood pressure or heart rate), or as add-on therapy to nitrates, β-blockers and calcium channel blockers [18]. Currently, ranolazine is indicated for patients with chronic stable angina, not for patients with stable ischemic heart disease. However, some suggest that there is a need for ranolazine in the broader CHD population, such as in those with cardiac X syndrome, who often have no response to conventional Thalidomide anti-anginal

therapy, or those with ischemic heart disease plus diabetes mellitus or arrthymias [19, 20]. While the high cost of ranolazine versus other anti-angina medications often leads to physicians opting to use ranolazine as a second-line or later treatment [18], the use of ranolazine in patients with poorly controlled angina is associated with decreases in revascularization rates, prescription costs, and a reduction in total care costs compared with patients receiving nitrates, β-blockers or calcium channel blockers [21]. Thus, the use of ranolazine can reduce the large financial burden chronic stable angina puts on the healthcare system. The improvements in QoL and severity of angina attacks reported by respondents on ranolazine in the present survey reflect the efficacy of outcomes tools such as the SAQ used to assess QoL in patients with chronic stable angina [13].

In order to investigate the robustness of the results, we recalcu

In order to investigate the robustness of the results, we recalculated cost savings after changing the values of key parameters (see Table 3). Since the LOS results exhibited large variance and the differences were not significant, potential cost savings or additional investments were calculated based on the 95% confidence interval of the LOS results. Cost saving results were found not to be robust when subject

to changes in duration of hospital stay of negative patients. All other parameter changes did not significantly alter the results (Table 3). Changes in the quantity of samples processed per year did not have a significant effect on cost savings even though a small potential of economies of scale based on capital investment and staff training selleck screening library costs might be more significant for large laboratories with high sample turnover (Table 3). Due to the lack of statistical

significance and Neratinib purchase large range and variance in LOS data, the results of this study cannot definitely confirm that cost savings will be made by using PCR. However, a clear trend can be observed when results are tested for robustness indicating a high potential for savings (Table 3). Table 3 Parameter changes and their effect on potential cost savings achieved by routine real-time PCR compared to routine CCNA for Clostridium difficile testing Parameter Base case value Changed value (applied change) Cost saving/patient (£) LOS of CDI-positive patients (days) −4.88 −19.39 (lower bound Selleck Lumacaftor 95% CI) 2,545.73 LOS of CDI-positive patients (days) −4.88 9.62 (upper bound 95% CI) 2,036.68 LOS of CDI-negative patients (days) −7.03 −20.66 (lower bound 95% CI) 6,609.60

LOS of CDI-negative patients (days) −7.03 6.60 (upper bound 95% CI) −2,024.35 Cost of consumables and materials for testing (CCNA/PCR) (£) 1.57/33.51 0.79/16.75 (50% discount applied) 2,307.84 Number of samples processed per year 10,000 15,000 (+50%) 2,292.47 Number of samples processed per year 10,000 5,000 (−50%) 2,293.07 Percentage of positive samples 2.68 5.36 (+100%) 2,256.59 Percentage of positive samples 2.68 1.34 (−100%) 2,311.35 Assumption that all CCNA-negative patients will be tested twice Negative patients tested twice Negative patients tested once 2,302.55 Assumption that all CCNA-negative patients will be tested twice Negative patients tested twice Negative patients tested three times 2,283.19 CCNA cell culture cytotoxin neutralization assay, CDI Clostridium difficile infection, CI confidence interval, LOS length of hospital stay, PCR polymerase chain reaction Discussion Fast and accurate laboratory results have been suggested to impact patient management and infection control measures [20]. The high sensitivity and specificity of PCR-based assays for C.

Biol Pharm Bull 2005, 28:1129–1131 CrossRef 20 Nosanchuk JD, Cas

Biol Pharm Bull 2005, 28:1129–1131.CrossRef 20. Nosanchuk JD, Casadevall A: Impact of melanin on microbial virulence and clinical resistance to antimicrobial compounds. Antimicrob Agents Chemother 2006, 50:3519–3528.PubMedCrossRef Carfilzomib datasheet 21. Wang Y, Aisen P, Casadevall A: Melanin, melanin “”ghosts,”" and melanin composition in Cryptococcus neoformans . Infect Immun 1996, 64:2420–2424.PubMed 22. Nosanchuk JD, van Duin D, Mandal P, Aisen P, Legendre AM, Casadevall A: Blastomyces dermatitidis produces melanin in vitro and during infection. FEMS Microbiol

Lett 2004, 239:187–193.PubMedCrossRef 23. Gomez BL, Nosanchuk JD, Diez S, Youngchim S, Aisen P, Cano LE, Restrepo A, Casadevall A, Hamilton AJ: Detection of melanin-like pigments in the dimorphic fungal pathogen Paracoccidioides brasiliensis in vitro and during infection. Infect Immun 2001, 69:5760–5767.PubMedCrossRef 24. Nosanchuk JD, Gomez BL, Youngchim S, Diez S, Aisen P, Zancope-Oliveira RM, Restrepo A, Casadevall A, Hamilton AJ: Histoplasma capsulatum synthesizes melanin-like pigments in vitro and during mammalian infection. Infect Immun 2002, 70:5124–5131.PubMedCrossRef 25. Morris-Jones R, Youngchim S, Gomez BL, Aisen P, Hay RJ, Nosanchuk JD, Casadevall A, Hamilton AJ: Synthesis

of melanin-like pigments by Sporothrix schenckii Osimertinib mouse in vitro and during mammalian infection. Infect Immun 2003, 71:4026–4033.PubMedCrossRef 26. Paolo WF Jr, Dadachova E, Mandal P, Casadevall A, Szaniszlo PJ, Nosanchuk filipin JD: Effects of disrupting the polyketide synthase gene WdPKS1 in Wangiella [Exophiala] dermatitidis on melanin production and resistance to killing by antifungal compounds, enzymatic degradation, and extremes in temperature. BMC Microbiol 2006, 6:55.PubMedCrossRef 27. Krzywda A, Petelenz E, Michalczyk D, Plonka PM: Sclerotia of the acellular (true) slime mould Fuligo septica as a model to study melanization and anabiosis. Cell Mol Biol Lett 2008, 13:130–143.PubMedCrossRef 28. Jacobson ES, Hong JD: Redox buffering by melanin and Fe(II) in Cryptococcus neoformans . J Bacteriol

1997, 179:5340–5346.PubMed 29. Herbst MH, Pinhal NM, Demétrio FAT, Dias GHM, Vugman NV: Solid-state structural studies on amorphous platinum-fullerene[60] compounds [PtnC60] (n = 1,2). Journal of Non-Crystalline Solids 2000, 272:127–130.CrossRef 30. Franzen AJ, Cunha MM, Batista EJ, Seabra SH, De Souza W, Rozental S: Effects of tricyclazole (5-methyl-1,2,4-triazol[3,4] benzothiazole), a specific DHN-melanin inhibitor, on the morphology of Fonsecaea pedrosoi conidia and sclerotic cells. Microsc Res Tech 2006, 69:729–737.PubMedCrossRef 31. Kataoka K, Muta T, Yamazaki S, Takeshige K: Activation of macrophages by linear (1right-arrow3)-beta-D-glucans. Impliations for the recognition of fungi by innate immunity. J Biol Chem 2002, 277:36825–36831.PubMedCrossRef 32.

Thirty samples of water, weeds, stones and sediments were collect

Thirty samples of water, weeds, stones and sediments were collected from each of these sites and transported at 4°C to the laboratory. Water samples were collected by submerging sterile 1 L glass bottles in the water to a depth of about 10 cm and then opened to fill after which they were closed and brought to surface. CDK phosphorylation About five grams (5 g) each of sediment materials, stones and weed in the water bodies were collected into bottles. All samples were processed within 12 hours of collection. About 1 ml

quantities of the water samples were separately inoculated into 20 ml molten Nutrient agars and Sabouraud agars (Merck, Nottingham, UK). The stones and weed samples were gently and separately scrubbed with sterile brush into10 ml sterile normal saline and 1 ml quantities were added to the molten agars. About 1 g of the soil samples were also suspended in 5 ml of normal saline and 1 ml of these suspensions were added to the agars. All the plates were incubated (Nutrient agars at 37°C and Sabouraud agars at 25°C) for seven days with daily observation. Colonies that appeared to have clear zones around them were carefully isolated into pure cultures.

Test microorganisms These microorganisms from the stocks kept by the Microbiology Laboratory of the Department of Pharmaceutics were used in the study: Bacillus thuringiensis (ATCC 13838), Staphylococcus aureus (ATCC 25923), Bacillus subtilis selleck chemicals (NCTC 10073), Pseudomonas aeruginosa (ATCC 27853), Proteus vulgaris (NCTC 4175), Enterococcus faecalis (ATCC 29212), Escherichia coli (clinical isolate), Salmonella typhi (clinical isolate) and Candida albicans (clinical isolate). Screening of isolated microorganisms

for inhibitory activity The isolates were screened for antibacterial metabolite production using the agar-well diffusion method. The inocula were prepared by growing the Unoprostone various test organisms on separate agar plates and colonies from the plate were transferred with inoculating loop into 3 ml of normal saline in a test tube. The density of these suspensions was adjusted to 0.5 McFarland standards. The surface of Muller-Hinton agar (Oxoid Cambridge, UK) plate was evenly inoculated with the test organisms using a sterile swab: the swab was dipped into the suspension and pressed against the side of the test tube to remove excess fluid. The wet swab was then used to inoculate the Muller-Hinton agar by evenly streaking across the surface. By means of a sterile cork borer wells (8 mm in diameter) were made in the agar and filled with 0.2 ml of 72 h culture of the isolate microorganism. Two replicates of the experiment were done and the plates incubated at 37°C for 18 h. The diameters of zone of growth-inhibition produced were measured and the mean values calculated (Table 1). Isolates MAI1, MAI2 and MAI3 produced the highest zones and were therefore selected for the next level of studies.

PDGFR-alpha expression was analyzed by immunohistochemistry, and

PDGFR-alpha expression was analyzed by immunohistochemistry, and expression was scored separately for epithelial cells, stroma fibroblasts and perivascular cells. In general, PDGFR-alpha expression was frequently seen in perivascular cells and fibroblasts, but not in epithelial cells. Fibroblast expression was up-regulated in tumors as compared to normal tissue. PDGFR-alpha

expression was higher in colon cancer fibroblasts than in rectal cancer fibroblasts. PDGFR-alpha expression in primary tumor CAFs was correlated with more advanced N stage. Several associations were observed between PDGFR-alpha expression in lymph find more node metastases and survival. Increased expression of PDGFR-alpha in lymph node fibroblasts was associated with worse survival in the whole patient cohort. High PDGFR-alpha expression in fibroblasts or pericytes in lymph nodes was associated with increased recurrence risk in curatively treated patients. The associations between

survival and stromal PDGFR-alpha lymph node expression were also significant in a multivariate analysis. Interestingly, also high expression of PDGFR-alpha in fibroblasts of normal mucosa was associated with worse over-all survival. These findings thus highlight the prognostic potential of tumor stroma and specifically demonstrate novel prognostic significance of stromal PDGFR-alpha in CRC. The associations between PDGFR-alpha status of normal mucosa and survival also points to the importance of “host factors” in tumor progression. Poster No. 58 Serum Levels PD0332991 concentration of Dermcidin Increase with Progression of Mammary Carcinogenesis OSBPL9 Heather Ann Brauer 1,2 , Tanya E. Libby1, Yutaka Yasui3, Anne McTiernan1, Henry J. Thompson4, Paul D. Lampe1,2 1 Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 2 Molecular and Cellular Biology Program, University of Washington, Seattle, WA, USA, 3 Department of Public Health Sciences, University of Alberta, Edmonton, AB, Canada,

4 Cancer Prevention Laboratory, Colorado State University, Fort Collins, CO, USA Early detection and prognostic profiling of cancers has the potential to increase lifespan and quality of life. The “field effect” hypothesis that motivated this investigation suggests that there are cellular changes that occur both within and around tumor cells that could be detectable in serum. These changes may be detectable before the disease is histologically identifiable using the current testing methods. This valuable information could potentially come from serum where early stages of tumorigenesis lead to changes in the serum peptidome. An experiment testing this idea was carried out using a rat model of mammary carcinoma. Samples were collected at different stages of progression and abundant proteins depleted to determine if MALDI-TOF mass spectrometry could provide a proteomic profile that could identify disease.

Although the microbiota in adults has been extensively studied, i

Although the microbiota in adults has been extensively studied, investigation into structural changes and compositional evolution from infants to the elderly has only recently begun. Very little information is available pertaining to possible variations that occur with ageing. In healthy adults, 80% of the identified fecal microbiota can be classified into three dominant phyla: Bacteroidetes, Firmicutes and Actinobacteria [6]. In general terms the Firmicutes

to Bacteroidetes ratio is MK-2206 molecular weight regarded to be of significant relevance in human gut microbiota composition [7]. On a more refined level, however, the fecal microbiota is a highly complex and diverse bacterial ecosystem. Within this ecosystems exists a hierarchy of dominant (> 109 Colony Forming Units (CFU)/g)) anaerobic bacteria, represented by the genera Bacteroides, Eubacterium, Bifidobacterium, Peptostreptococcus, Ruminococcus, Clostridium and Propionibacterium, and sub-dominant (< 109 CFU/g), bacteria of the Enterobacteriaceae family, especially E. coli, and the genera Streptococcus, Enterococcus, Lactobacillus, Fusobacterium, Desulfovibrio and Methanobrevibacter [8]. Establishment of the intestinal microbiota has been shown to be a progressive process [9]. This process of increasing PLX4720 diversity is required for proper development and is important for overall health.

The major functions attributed to the microbiota present in the gut begin to manifest at the end of the second year of life and comprise: i) nutrients absorption and food fermentation [10], ii) stimulation of the host immune system [11] and iii) barrier effects against pathogens [12]. Once climax composition

is achieved near the end of adolescence, 4��8C this ecosystem displays a high stability in healthy adults [13]. Although the intestinal microbiota is relatively stable throughout adult life, recent studies indicated that modifications occur in the composition in elderly individuals. For example, a reduction in the numbers of Bifidobacteria and Bacteroides has been observed, accompanied also by a decrease of Lactobacilli. A commensurate increase in the number of facultative anaerobes also highlights the variation between adults and elderly individuals [14–17]. Such variation was also observed by Ley et al. [7] when a correlation between body weight and gut microbial ecology was analysed. The microbiota in obese subjects shows an elevated proportion of Firmicutes and a reduced population of Bacteroides. Conversely, a decreased Firmicutes/Bacteroidetes ratio has been directly related to weight loss [7]. The work presented here aims to continue to expand our understanding of the intestinal flora including its establishment, composition, and evolution. To that end, we focused on the important ratio between Firmicutes and Bacteroidetes. We used a qPCR-based approach to enumerate changes in bacterial populations in the human intestine.

iii) Trichoderma citrinoviride strains S 25 and IMI 91968 are ric

iii) Trichoderma citrinoviride strains S 25 and IMI 91968 are rich sources of 20-residue peptaibols of the paracelsin/saturnisporin/trichocellin/suzukacillin/trichoaureocin-type.

Selleck Ixazomib These are the only two strains of T. citrinoviride that have been investigated for peptaibiotics. Hypocrea schweinitzii ICMP 5421, which has also been verified phylogenetically (Réblová and Seifert 2004), had only been screened positive for Aib by GC/MS; but − to the best of the authors’ knowledge − specimens of that species have never been investigated for its inventory of peptaibiotics. Parcelsins, which have been isolated from T. reesei QM 9414, are also produced by a member of the Longibrachiatum clade. However,

the producer of saturnisporin (T. saturnisporum MNHN 903578: Rebuffat et al. 1993) has never been made publicly available, nor has its identity been verified phylogenetically. The producers of both trichocellins and suzukacillins A (Krause et al. 2006b) have not been deposited in a publicly available culture collection; thus, their identification as T. ‘viride’ is highly questionable.   iv) T. flavofuscum CBS 248.59 is the only species of Trichoderma/Hypocrea, which produces 13-residue sequences − notably trichofumins C and D are the only two peptaibols of that chain length reported to date. They display the rare Gln-Gln motif in positions 5 and PLEK2 6. Looking at the sequences, their biosynthesis seems to be distantly related to that one of trichofumins A and B (and positional

Selleckchem BVD-523 isomers thereof). The latter are 11-residue SF4-peptaibols and widespread amongst Trichoderma/Hypocrea species.   v) T. virens strain Tv29-8 produces common 11- and 14-residue peptaibols, and it is the only phylogenetically verified source of 18-residue peptaibols of the trichorzin-type.   However, the results of our LC-MS/MS screening are also of interest for analysis of environmental samples as well as extraterrestrial materials such as carbonaceous meteorites as their contamination by propagules of soil- or airborne peptaibiotic-producing fungi has to be taken into account (Brückner et al. 2009; Elsila et al. 2011). To sum up, production of peptaibiotics may generally be regarded as a sophisticated ecological adaptation for the producing fungus providing it with an obvious advantage over non-producing fungal and other competitors. This group of ‘chemical weapons’ in their ‘armoury’ may effectively assist a remarkable number of strains currently identified as belonging to ca. 30 Trichoderma/Hypocrea species in colonising and defending their ecological niches. Acknowledgments This study was supported by the Hessian Ministry for Science and Art by a grant from the LOEWE-Schwerpunkt ‘Insect Biotechnology’ to Andreas Vilcinskas.

The distance mark in (a) indicates the range of the nanoporous ba

The distance mark in (a) indicates the range of the nanoporous base layer underneath the Au film and the nanopillars. Figure 3 SEM images of nanopillars formed from the highly doped Si after 10-min etching. In (a) λ 1, (b) λ 2, (c) λ 3, and (d) λ 4 solutions. The distance mark

in (d) indicates the range of the nanoporous base layer under the Au film and nanopillars. The highly doped Si was etched for 10 min in solutions with different values of the molar ratio λ, and the formed nanopillars are shown in Figure 3. Relatively long nanopillars and a thin nanoporous base layer were observed after etching in the λ 1, λ 2, and λ 3 solutions, while shorter nanopillars and a thick homogenous nanoporous base layer with a thickness of 4.3 μm below the pillars were observed after etching in the λ 4 solution. The nanoporosity of the nanopillars etched in the λ 1, λ 2, and λ 4 solutions becomes obvious in the cracked pillars (Additional Decitabine cell line AZD6244 manufacturer file 1: Figure S2). After 10-min etching in the λ 1 and λ2 solutions (Additional file 1: Figure S2a,b), it was also observed that the nanoporous base layer below the pillars is thicker than that directly below the Au film. The nanopillars are strongly bent and bonded together at the top after etching in the λ 1 solution (Figure 3a).

The bonded nanopillars at the top can be clearly seen in the magnified SEM image (Additional file 1: Figure S3). In addition, the thickness of these nanopillars is about 50% smaller at the top compared to the bottom of the pillars. The bonded and bent nanopillars were also observed after etching in the λ 2 solution (Figure 3b), but they are less bent than those after etching in the λ 1 solution. The nanopillars etched in the λ 1 solution were bonded as bundles, while the nanopillars etched in the λ 2 solution were

bonded in rows (Additional file 1: Figure S4a,b). The same thickness is seen both at the top and bottom of the nanopillars etched in the λ 2 solution. Long isolated nanopillars without bending were observed after etching in the λ3 solution (Figure 3c). The dependence of the bonding and bending phenomena on the STK38 value λ is more clearly seen in the tilted SEM images (Additional file 1: Figure S4). The lightly doped Si was etched for 10 min in solutions with different values of λ, and the formed nanopillars are shown in Figure 4. The etching in the λ 1 solution was not homogenous, and at some places, only a nanoporous base was etched underneath the Au film, while at other places, nanopillars with a nanoporous base were observed, and somewhere else, nanopillars without a nanoporous base layer were observed (Additional file 1: Figures S5 and S6). The nanopillars were strongly bonded together at the top and strongly bent after etching in the λ 1 and λ 2 solutions (Figure 4a,c). The thickness on top of the nanopillars is reduced to about 40% and 55% after etching in the λ 1 and λ 2 solutions for 10 min.

From this gene set 39 genes were W83-specific as they were absent

From this gene set 39 genes were W83-specific as they were absent in each of the test strains. In this way the prtT protease gene and a fimbrillin gene (fimA) were found to be aberrant in all test strains, but not W83-specific as they were present in one or more test strains. The results for fimA support the findings that the gene is widely distributed, but variable at the probe locus among P. gingivalis strains. Many of the genes found in this analysis are located within the highly variable regions described in earlier publications using whole-genome analysis. The existence of those regions were supported by data comparing the genome sequences

of P. gingivalis strains W83 and ATCC33277 [28]. Also in this study we found these regions

back in the analysis as described above Genes Selleck 5-Fluoracil only aberrant in FDC381 FDC381 is the only strain included in this study that does not produce CPS. It is also the least virulent strain in mouse studies. Here, an Bortezomib analysis was performed to find genes that are specifically aberrant in FDC381 and not in all the other test strains (Table 7). Alongside many genes encoding hypothetical proteins several genes of special interest were found. The genes PG1711 encoding an alpha-1,2-mannosidase family protein, and PG1972 encoding the hemagglutinin hagB, all thought to be involved in virulence either by a role in evasion of the immune system or by a role in adhesion to host cells [29, 59]. Table 7 Genes only aberrant in strain FDC381 GeneID Annotated function PG0183 lipoprotein, heptaminol putative PG0204 hypothetical protein PG0300 TPR domain protein PG0492 hypothetical protein PG1119 flavodoxin, putative PG1199 hypothetical protein PG1200 hypothetical protein PG1373 hypothetical protein PG1466 hypothetical protein PG1467 methlytransferase, UbiE-COQ5 family PG1473 conjugative transposon protein TraQ PG1685 hypothetical protein PG1711 alpha-1,2-mannosidase family protein PG1777 conserved

hypothetical protein PG1786 hypothetical protein PG1814 DNA primase PG1969 hypothetical protein PG1970 hypothetical protein PG1972 hemagglutinin protein HagB PG1977 hypothetical protein PG1978 hypothetical protein Although these data do not directly show any CPS biosynthesis specific genes aberrant only in the non-encapsulated FDC381 it does give hints towards other virulence associated traits that are missing in FDC381. High versus lower virulence strains When comparing the core gene set of only the highly virulent strains W83, HG1025, ATCC49417 and HG1690 with the genes aberrant in each of the less virulent strains HG184, HG1691, 34-4 and FDC381 an interesting result was seen. There is only a single gene, hmuS, that is present in all highly virulent strains but aberrant in each of the less virulent strains. HmuS is part of the hmuYRSTUV haemin uptake system [60].

Mol Microbiol 2006,60(2):274–286 10 1111/j 1365-2958 2006 05081

Mol Microbiol 2006,60(2):274–286. 10.1111/j.1365-2958.2006.05081.x145331116573680CrossRefPubMedCentralPubMed 31. Lambert C, Fenton AK, Hobley L, Sockett RE: Predatory bdellovibrio bacteria Use gliding PCI 32765 motility to scout for prey on surfaces. J Bacteriol 2011,193(12):3139–3141. 10.1128/JB.00224-11313321521515772CrossRefPubMedCentralPubMed 32. Lambert C, Smith MCM, Sockett RE: A novel assay to monitor predator–prey interactions for Bdellovibrio bacteriovorus 109 J reveals a role for methyl-accepting chemotaxis proteins in predation. Environ Microbiol 2003,5(2):127–132. 10.1046/j.1462-2920.2003.00385.x12558595CrossRefPubMed

33. Atterbury RJ, Hobley L, Till R, Lambert C, Capeness MJ, Lerner TR, Fenton AK, Barrow P, Sockett RE: Effects of orally administered bdellovibrio bacteriovorus on the well-being and salmonella colonization of young chicks. Appl Environ Microbiol 2011,77(16):5794–5803. 10.1128/AEM.00426-11316524321705523CrossRefPubMedCentralPubMed 34. Scherff RH: Control of bacterial CHIR-99021 purchase blight of soybean by Bdellovibrio

bacteriovorus. Phytopathology 1973,63(3):400–402. 10.1094/Phyto-63-400CrossRef 35. Frey-Klett P, Burlinson P, Deveau A, Barret M, Tarkka M, Sarniguet A: Bacterial-fungal interactions: hyphens between agricultural, clinical, environmental, and food microbiologists. Microbiol Mol Biol Rev 2011,75(4):583−+. 323273622126995CrossRefPubMedCentralPubMed 36. Rainey PB: Phenotypic variation of Pseudomonas-Putida

and P-TolaasII affects attachment to Agaricus-Bisporus mycelium. J Gen Microbiol 1991, 137:2769–2779. 10.1099/00221287-137-12-27691791432CrossRefPubMed 37. Russo A, Filippi C, Tombolini R, Toffanin A, Bedini S, Agnolucci M, Nuti M: Interaction between gfp-tagged Pseudomonas tolaasii P12 and Pleurotus eryngii. Microbiol Res 2003,158(3):265–270. 10.1078/0944-5013-0020314521237CrossRefPubMed 38. Morehouse KA, Hobley L, Capeness M, Sockett RE: Three motAB stator gene products in bdellovibrio bacteriovorus contribute to motility IMP dehydrogenase of a single flagellum during predatory and prey-independent growth. J Bacteriol 2011,193(4):932–943. 10.1128/JB.00941-10302868321148728CrossRefPubMedCentralPubMed 39. Sajben E, Manczinger L, Nagy A, Kredics L, Vagvolgyi C: Characterization of pseudomonads isolated from decaying sporocarps of oyster mushroom. Microbiol Res 2011,166(4):255–267. 10.1016/j.micres.2010.05.00220627228CrossRefPubMed 40. Shankar M, Ponraj P, Ilakkiam D, Gunasekaran P: Root colonization of a rice growth promoting strain of Enterobacter cloacae. J Basic Microbiol 2011,51(5):523–530. 10.1002/jobm.20100034221656802CrossRefPubMed 41. Watabe M, Rao JR, Xu J, Millar BC, Ward RF, Moore JE: Identification of novel eubacteria from spent mushroom compost (SMC) waste by DNA sequence typing: ecological considerations of disposal on agricultural land. Waste Manag 2004,24(1):81–86. 10.1016/j.wasman.2003.08.00114672727CrossRefPubMed 42.